Alnylam closes in on approval of third RNAi therapeutic

17 December 2019

US biotech Alnylam Pharmaceuticals (Nasdaq: ALNY) cemented its standing as the leading RNAi therapeutics company on Tuesday by presenting positive Phase III data on its latest candidate.

Following in the footsteps of Alnylam’s two approved therapies, lumasiran met all primary and secondary tested endpoints in the ILLUMINATE-A study in primary hyperoxaluria type 1 (PH1), with significant reduction in urinary oxalate levels relative to placebo.

Based on these results, Alnylam plans to submit a New Drug Application in the USA and file a Marketing Authorisation Application to the European Medicines Agency for lumasiran in early 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK